BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 22918549)

  • 1. The risk of a second primary lung cancer after a first invasive breast cancer according to estrogen receptor status.
    Schonfeld SJ; Curtis RE; Anderson WF; Berrington de González A
    Cancer Causes Control; 2012 Oct; 23(10):1721-8. PubMed ID: 22918549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Declining second primary ovarian cancer after first primary breast cancer.
    Schonfeld SJ; Berrington de Gonzalez A; Visvanathan K; Pfeiffer RM; Anderson WF
    J Clin Oncol; 2013 Feb; 31(6):738-43. PubMed ID: 23284037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in the risk of radiation-related contralateral breast cancer by histology and estrogen receptor expression in SEER.
    Neta G; Anderson WF; Gilbert E; Berrington A
    Breast Cancer Res Treat; 2012 Feb; 131(3):1021-7. PubMed ID: 22015617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries.
    Berrington de Gonzalez A; Curtis RE; Gilbert E; Berg CD; Smith SA; Stovall M; Ron E
    Br J Cancer; 2010 Jan; 102(1):220-6. PubMed ID: 19935795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis.
    Liu J; Jiang W; Mao K; An Y; Su F; Kim BY; Liu Q; Jacobs LK
    Breast Cancer Res Treat; 2015 Apr; 150(2):439-45. PubMed ID: 25764167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second primary breast cancer occurrence according to hormone receptor status.
    Kurian AW; McClure LA; John EM; Horn-Ross PL; Ford JM; Clarke CA
    J Natl Cancer Inst; 2009 Aug; 101(15):1058-65. PubMed ID: 19590058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer.
    Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI
    Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Second Primary Female Genital Malignancies in Women with Breast Cancer: a SEER Analysis.
    Li Z; Wu Q; Song J; Zhang Y; Zhu S; Sun S
    Horm Cancer; 2018 Jun; 9(3):197-204. PubMed ID: 29556910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone receptor status of contralateral breast cancers: analysis of data from the US SEER population-based registries.
    Mezencev R; Švajdler M
    Breast Cancer; 2017 May; 24(3):400-410. PubMed ID: 27502779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up.
    Marees T; Moll AC; Imhof SM; de Boer MR; Ringens PJ; van Leeuwen FE
    J Natl Cancer Inst; 2008 Dec; 100(24):1771-9. PubMed ID: 19066271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status.
    Sung H; Freedman RA; Siegel RL; Hyun N; DeSantis CE; Ruddy KJ; Jemal A
    Cancer; 2021 Sep; 127(18):3310-3324. PubMed ID: 34002851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of contralateral breast cancer according to first breast cancer characteristics among women in the USA, 1992-2016.
    Ramin C; Withrow DR; Davis Lynn BC; Gierach GL; Berrington de González A
    Breast Cancer Res; 2021 Feb; 23(1):24. PubMed ID: 33596988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.
    Travis LB; Fosså SD; Schonfeld SJ; McMaster ML; Lynch CF; Storm H; Hall P; Holowaty E; Andersen A; Pukkala E; Andersson M; Kaijser M; Gospodarowicz M; Joensuu T; Cohen RJ; Boice JD; Dores GM; Gilbert ES
    J Natl Cancer Inst; 2005 Sep; 97(18):1354-65. PubMed ID: 16174857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of second primary cancer among women in the Kaiser Permanente Breast Cancer Survivors Cohort.
    Ramin C; Veiga LHS; Vo JB; Curtis RE; Bodelon C; Aiello Bowles EJ; Buist DSM; Weinmann S; Feigelson HS; Gierach GL; Berrington de Gonzalez A
    Breast Cancer Res; 2023 May; 25(1):50. PubMed ID: 37138341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second cancers following in situ carcinoma of the breast.
    Franceschi S; Levi F; La Vecchia C; Randimbison L; Te VC
    Int J Cancer; 1998 Jul; 77(3):392-5. PubMed ID: 9663601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of a second breast cancer associated with hormone-receptor and HER2/neu status of the first breast cancer.
    Bessonova L; Taylor TH; Mehta RS; Zell JA; Anton-Culver H
    Cancer Epidemiol Biomarkers Prev; 2011 Feb; 20(2):389-96. PubMed ID: 21217087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second malignancies after adjuvant radiation therapy for early stage breast cancer: is there increased risk with addition of regional radiation to local radiation?
    Hamilton SN; Tyldesley S; Li D; Olson R; McBride M
    Int J Radiat Oncol Biol Phys; 2015 Apr; 91(5):977-85. PubMed ID: 25832690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiotherapy for ductal carcinoma in situ and risk of second non-breast cancers.
    Withrow DR; Morton LM; Curtis RE; Schonfeld SJ; Berrington de González A
    Breast Cancer Res Treat; 2017 Nov; 166(1):299-306. PubMed ID: 28744752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries.
    Berrington de Gonzalez A; Curtis RE; Kry SF; Gilbert E; Lamart S; Berg CD; Stovall M; Ron E
    Lancet Oncol; 2011 Apr; 12(4):353-60. PubMed ID: 21454129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body mass index, weight change, and risk of second primary breast cancer in the WECARE study: influence of estrogen receptor status of the first breast cancer.
    Brooks JD; John EM; Mellemkjaer L; Lynch CF; Knight JA; Malone KE; Reiner AS; Bernstein L; Liang X; Shore RE; Stovall M; ; Bernstein JL
    Cancer Med; 2016 Nov; 5(11):3282-3291. PubMed ID: 27700016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.